

Cancer Disparities Research Partnership

(CDRP) U54 Program Process & Outcome Evaluation

Lisbeth Jarama, PhD, *Project Manager*

Natalie Gay, MS, *Project Coordinator*

Paul Young, MBA, MPH, *Project Director*

NOVA Research Company



Purpose of Evaluation

- ◆ Measure relevance, effectiveness, and impact of CDRP U54 Program
 - Stabilize and improve current clinical research infrastructure
 - Enhance/extend partnership clinical trial collaboration
 - Enhance accrual of underserved population to cancer control, prevention, and treatment trials
 - Meet other U54 implementation objectives
- ◆ Conduct process and outcome evaluation

Evaluation Questions

- How have program capabilities been stabilized (i.e., research infrastructure, training, outreach, patient navigation, and partner collaboration)?
- Has there been an increase of minority and underserved patient accrual into clinical trials?
- Has additional non-NCI funding been secured?
- What are plans for sustainability after U54?
- Have CCOP/MB-CCOP requirements been met?
- To what extent have grantees met other process and intermediate outcome goals?

CDRP U54 Program Evaluation Methodology

◆ Other:

- Program-related written documents (e.g., PI meeting minutes, annual progress reports, baseline clinical trial data at sites, RTOG PSC presentations)
- Quarterly site data submissions
- In-depth PI interviews

Evaluation Timeline—1st Year

(September 2010 – August 2011)

- *4-Year Evaluation (September 2010 – August 2014)*
- **Finalize U54 Data Elements – November**
 - Identify metrics (currently working with NCI/RRP)
 - Obtain input from PIs and key program staff – week of Nov 15
- **Develop Data Dictionary – November**
 - Include data metrics, response options, and definitions
 - Obtain input from NCI/RRP and CDRP EAC
 - Obtain input from PIs and key program staff – week of Nov 15
- **Develop Excel Spreadsheet Template – November**
 - Obtain input from PIs and key program staff - late November
- **Distribute Excel Template /Data Dictionary – early Dec**

Evaluation Timeline—1st Year

(continued)

- **Site Quarterly Data Submissions:**
 - Next submission due on Nov 15, 2010 – use existing forms
 - New Excel template - 15th of Feb, May, and Aug 2011
- **NOVA Quarterly Program Data Report – December 17, 2010**
- **Quarterly Program Data Report to PIs – January 2011**
- **PI Interviews – February/March 2011**
- **NOVA Annual Progress Report - October 13, 2011**
- **Annual Evaluation Advisory Committee Meeting**

CDRP U54 Program Data Elements— Highlights

■ Research Staff

- Program staff changes/turnover, % funded by CDRP grant

■ Clinical Trials/Protocols

- Modified clinical trial/research summary spreadsheet
- Protocol name/number and opened/closed dates
- **Seven Protocol Type Categories:**
 - PI-Initiated
 - RTOG
 - NCI/CTEP Cooperative Group
 - Social Science Study
 - Mentor/Partner-Initiated
 - NCI/DCP
 - Pharmaceutical/Industry
- # patients accrued to each protocol (except social science studies)

U54 Data Elements—Highlights (cont.)

- **Patient Data (Aggregated)**
 - # patients requiring follow-up (U56 and U54)
 - # new patients screened, eligible, accrued, by demographics:
 - Race/ethnicity and gender
 - **Non-Hispanic Whites ONLY**
 - Insurance status: no insurance, private, Medicare, Medicaid
 - Elderly: 65 and older
 - # patients accrued to PI-initiated, mentor/partner-initiated, RTOG, NCI/DCP, NCI/CTEP Cooperative Group, pharmaceutical/industry
 - Reasons patients refused CT participation and reasons patients found ineligible

U54 Data Elements—Highlights (cont.)

■ Patient Navigation

- Caseload (# new and prior) of patients navigated
- # new patients navigated, refusing navigation, and navigated and enrolled to CT, by demographics:
 - Race/ethnicity and gender
 - **Non-Hispanic Whites ONLY**
 - Insurance status: no insurance, private, Medicare, Medicaid
 - Elderly: 65 and older
- Reasons patients refused navigation

■ Publications and Presentations, Additional Funding, and Project-Generated Resources